Analyst Caitlin Cronin from Canaccord Genuity maintained a Buy rating on Stryker (SYK – Research Report) and keeping the price target at $435.00.
Caitlin Cronin has given her Buy rating due to a combination of factors including Stryker’s recent positive financial updates and strategic decisions. The company has increased its top-line organic growth guidance to 9.0%, reflecting a strong performance outlook. Additionally, the acquisition of Inari Medical is expected to contribute positively to Stryker’s financials, as updated income expectations have been incorporated into the model. The sale of the US spinal implants business and the exclusion of OUS spinal implants from operational results are strategic moves that streamline operations and focus on core areas.
Caitlin Cronin’s valuation approach further supports the Buy rating, with a price target of $435 based on a 29.3x P/E multiple. This multiple represents a 21% premium compared to the 2025 mean of large-cap MedTech peers, indicating confidence in Stryker’s future earnings potential. The pro forma EPS estimate for 2026 is projected at $14.85, reinforcing the positive outlook for the company’s growth and profitability.
Cronin covers the Healthcare sector, focusing on stocks such as Smith & Nephew Snats, Stryker, and SI-Bone. According to TipRanks, Cronin has an average return of 0.3% and a 44.05% success rate on recommended stocks.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $443.00 price target.